Patents by Inventor Biswajit KALITA

Biswajit KALITA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREX1 INHIBITORS AND USES THEREOF
    Publication number: 20230234943
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 (“TREX1”).
    Type: Application
    Filed: June 25, 2021
    Publication date: July 27, 2023
    Inventors: Thomas Walter DUBENSKY, JR., Ryan C. CLARK, Justin ERNST, Garrick K. PACKARD, Brett BUSCH, Joe Fred NAGAMIZO, Biswajit KALITA, Athisayamani Jeyaraj DURAISWAMY
  • CHEMICAL COMPOUNDS
    Publication number: 20230165848
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4 R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 1, 2023
    Inventors: Jeffrey Michael AXTEN, Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Raghava Reddy KETHIRI, Biswajit KALITA
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20230039846
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: July 6, 2021
    Publication date: February 9, 2023
    Inventors: Chun Jiang, Ruihong Chen, Anjali Pandey, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Chemical compounds
    Patent number: 11547704
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: January 10, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
  • PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS
    Publication number: 20220227765
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: August 26, 2020
    Publication date: July 21, 2022
    Inventors: Anjali Pandey, Chun Jiang, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • BENZIMIDAZOLE AND HYDROGENATED CARBAZOLE DERIVATIVES AS GPX4 INHIBITORS
    Publication number: 20220227716
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: August 26, 2020
    Publication date: July 21, 2022
    Inventors: Anjali Pandey, Chun Jiang, Biswajit Kalita
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20220002280
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: April 5, 2021
    Publication date: January 6, 2022
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Compounds and methods of use
    Patent number: 11098040
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: August 24, 2021
    Assignee: Ferro Therapeutics, Inc.
    Inventors: Chun Jiang, Ruihong Chen, Anjali Pandey, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Compounds and methods of use
    Patent number: 11040964
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: June 22, 2021
    Assignee: Ferro Therapeutics, Inc.
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES
    Publication number: 20210145771
    Abstract: The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 20, 2021
    Inventors: Mui CHEUNG, Michael P. DEMARTINO, Biswajit KALITA
  • Chemical Compounds as ATF-4 Pathway Inhibitors
    Publication number: 20210093619
    Abstract: The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula IIIQ: wherein X6?, a, b, C8?, D8?, L82?, L83?, R81?, R82?, R83?, R84?, R85?, R86?, z82?, z84?, z85?, and z86? are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 1, 2021
    Inventors: Jeffrey Michael AXTEN, Michael P. DEMARTINO, Karen Anderson EVANS, Biswajit KALITA, Jeffrey M. RALPH
  • Chemical compounds
    Patent number: 10851053
    Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 1, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Anthony William Dean, Michael P. DeMartino, Hilary Schenck Eidam, Biswajit Kalita, Raghava Reddy Kethiri, Rajendra Kristam
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20200299283
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: February 27, 2020
    Publication date: September 24, 2020
    Inventors: Chun Jiang, Anjali Pandey, Ruihong Chen, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Chemical Compounds
    Publication number: 20200297710
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Inventors: Jeffrey Michael AXTEN, Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Raghava Reddy KETHIRI, Biswajit KALITA
  • 2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES
    Publication number: 20200140383
    Abstract: The invention is directed to substituted azetidine derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein C, D, L1, L2, L3, R1, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein; and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 7, 2020
    Inventors: Mui CHEUNG, Michael P. DEMARTINO, Biswajit KALITA, Rajendra KRISTAM
  • Chemical Compounds
    Publication number: 20190298705
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 3, 2019
    Inventors: Jeffrey Michael AXTEN, Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Raghava Reddy KETHIRI, Biswajit KALITA
  • COMPOUNDS AND METHOD OF USE
    Publication number: 20190263802
    Abstract: This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 29, 2019
    Inventors: Chun Jiang, Ruihong Chen, Anjali Pandey, Biswajit Kalita, Athisayamani Jeyaraj Duraiswamy
  • Chemical Compounds
    Publication number: 20190144384
    Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 16, 2019
    Inventors: Jeffrey Michael AXTEN, Mui CHEUNG, Anthony William DEAN, Michael P. DEMARTINO, Hilary Schenck EIDAM, Biswajit KALITA, Raghava Reddy KETHIRI, Rajendra KRISTAM